Farmacia Hospitalaria (English Edition)最新文献_第10页

Quality of interaction database management systems 交互数据库管理系统的质量

Farmacia Hospitalaria (English Edition) Pub Date : 2009-01-01 DOI: 10.1016/S2173-5085(09)70079-6

A. Rodríguez-Terol , M.O. Caraballo , D. Palma , B. Santos-Ramos , T. Molina , T. Desongles , A. Aguilar

{"title":"Quality of interaction database management systems","authors":"A. Rodríguez-Terol , M.O. Caraballo , D. Palma , B. Santos-Ramos , T. Molina , T. Desongles , A. Aguilar","doi":"10.1016/S2173-5085(09)70079-6","DOIUrl":"10.1016/S2173-5085(09)70079-6","url":null,"abstract":"<div><h3>Objective</h3><p>To identify drug interaction databases (DID) and assess the quality of their structures.</p></div><div><h3>Method</h3><p>A search was made of the literature for DID and a series of exclusion and structural quality criteria were defined (at least 4 quality criteria: classification according to severity, classification according to level of evidence, bibliographical reference data, description of clinical management, and 11 criteria used for weighting). The level of compliance of every DID with the criteria defined was analysed, together with the level of compliance of each criteria in each DID.</p></div><div><h3>Results</h3><p>A total of 54 DID were identified, 30 of which complied with exclusion criteria and 15 of which did not meet the minimum criteria. The rest of the criteria were evaluated in 9 DID: Botplus and Medinteract (100%), SEFH Guide, Lexi-interact and Medscape (89%), Hansten (83%), Micromedex and Stockley (78%), Drug Interactions Facts (68%). Ninety-two percent of the DID describe the mechanism of action, 87% classify the information according to the active ingredient, 75% do not state they have any conflict of interest, classify according to level of severity, have electronic format, and are easy to search. A total of 67% are specific DID, 62% are classified according to level of evidence, contain bibliographical references, and describe clinical management.</p></div><div><h3>Conclusions</h3><p>A third of the DID comply with the minimum criteria. Differences were observed in the level and compliance criteria among Spanish and foreign DID. Some of the main DID used as references in the bibliography have significant structural defects: no web presentation, no multi-check function and others.</p></div>","PeriodicalId":100521,"journal":{"name":"Farmacia Hospitalaria (English Edition)","volume":"33 3","pages":"Pages 134-146"},"PeriodicalIF":0.0,"publicationDate":"2009-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S2173-5085(09)70079-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86096556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 24

Analysis of prescriptions given on discharge from the emergencies department. Economic impact 急诊科出院处方分析。经济的影响

Farmacia Hospitalaria (English Edition) Pub Date : 2009-01-01 DOI: 10.1016/S2173-5085(09)70077-2

J. Ruiz-López , M.A. Calleja Hernández , A. Giménez Manzorro , M. Sanjurjo Sáez

{"title":"Analysis of prescriptions given on discharge from the emergencies department. Economic impact","authors":"J. Ruiz-López , M.A. Calleja Hernández , A. Giménez Manzorro , M. Sanjurjo Sáez","doi":"10.1016/S2173-5085(09)70077-2","DOIUrl":"10.1016/S2173-5085(09)70077-2","url":null,"abstract":"<div><h3>Objective</h3><p>To analyse the characteristics and cost of medical prescriptions given upon discharge from the casualty department, as well as the savings made by making substitutions with generis drugs or other equivalent pharmaceutical products in a third level hospital.</p></div><div><h3>Methods</h3><p>Six hundred sixty-nine patients were chosen using a cluster sample with a sub-sample. The following variables were considered: <em>a)</em> analysis of the prescription (medication quantification, active ingredients and most prescribed therapeutic groups, and possibility of prescribing generis drugs); <em>b)</em> calculation of cost and saving estimate (price to public and equivalent products); and <em>c)</em> prescription quality (adherence to the guide and percentage of products of high therapeutic use.)</p></div><div><h3>Results</h3><p>Three hundred seventy of the 669 patients received medication when they were discharged, with an average of 1.7 per patient. Six hundred twenty-nine products were prescribed, 16% due to their active ingredient, with 37.53% generic products available. The main active ingredients prescribed were paracetamol, ibuprofen, and omeprazole amounting to 26.70% of the total prescribed and the therapeutic groups that were highlighted were locomotor apparatus, the nervous system, the digestive apparatus, and metabolism with 69.39% of the total. Ninety-two point eighty-four pecent of the prescriptions adhered to the pharmacotherapeutic guide and 98.41% were of high therapeutic use. The annual cost of prescribed medication was €1 013 778 and the saving made by generic product substitution and a programme of therapeutic equivalents was €145 971.</p></div><div><h3>Conclusions</h3><p>A prescription based on its active ingredients and a therapeutic and generis substitution produce a significant saving both for the patient and for the hospital.</p></div>","PeriodicalId":100521,"journal":{"name":"Farmacia Hospitalaria (English Edition)","volume":"33 2","pages":"Pages 104-110"},"PeriodicalIF":0.0,"publicationDate":"2009-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S2173-5085(09)70077-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90279883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Establishment of a quality indicator for pharmaceutical care 建立药学服务质量指标

Farmacia Hospitalaria (English Edition) Pub Date : 2009-01-01 DOI: 10.1016/S2173-5085(09)70093-0

M. Gaspar , M. Caja , I. Romero , L. Moreno Royo , A. García-Vivó , V. Tudela , M. Piquer

{"title":"Establishment of a quality indicator for pharmaceutical care","authors":"M. Gaspar , M. Caja , I. Romero , L. Moreno Royo , A. García-Vivó , V. Tudela , M. Piquer","doi":"10.1016/S2173-5085(09)70093-0","DOIUrl":"10.1016/S2173-5085(09)70093-0","url":null,"abstract":"<div><h3>Objective</h3><p>To establish a quality indicator for pharmaceutical care in an integral system for personalised medication dispensing (ISPMD) with electronic prescription.</p></div><div><h3>Methods</h3><p>Descriptive transversal study. Period: 2007. On a daily basis, we revised the pharmaceutical treatment of patients admitted to hospital units with ISPMD. Study variables: a) suitability of pharmaceutical interventions: important or very important; b) acceptance of those interventions. The LASER® method was used to identify patients with improvement opportunities.</p></div><div><h3>Results</h3><p>In absolute terms (mean [SD]): important pharmaceutical interventions, 26.6 (14.8); very important, 31.5 (24.6); acceptance, 57.5 (25.9). Percentages (95% CI): pharmaceutical interventions: important, 33.7 (9.3–58.0); very important, 39.80 (17.7–62.2); acceptance, 72.6 (64.7–80.5).</p></div><div><h3>Conclusions</h3><p>Implementation of the quality indicator for pharmaceutical care allowed us to evaluate the clinical significance and the acceptance rate of the pharmaceutical care being provided.</p></div>","PeriodicalId":100521,"journal":{"name":"Farmacia Hospitalaria (English Edition)","volume":"33 6","pages":"Pages 296-304"},"PeriodicalIF":0.0,"publicationDate":"2009-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S2173-5085(09)70093-0","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73758100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Study of rituximab efficacy, cost, safety, and compliance of its package leaflet in a tertiary hospital 某三级医院利妥昔单抗疗效、成本、安全性及包装说明书依从性的研究

Farmacia Hospitalaria (English Edition) Pub Date : 2009-01-01 DOI: 10.1016/S2173-5085(09)70094-2

M.C. Conde García , M.A. Fernández Feijoo , M.A. Calleja Hernández

{"title":"Study of rituximab efficacy, cost, safety, and compliance of its package leaflet in a tertiary hospital","authors":"M.C. Conde García , M.A. Fernández Feijoo , M.A. Calleja Hernández","doi":"10.1016/S2173-5085(09)70094-2","DOIUrl":"10.1016/S2173-5085(09)70094-2","url":null,"abstract":"<div><h3>Introduction</h3><p>The appearance of monoclonal antibodies, and specifically, rituximab, has provided a new approach to treating non-Hodgkin's lymphomas and rheumatoid arthritis. The purpose of this study is to analyse whether this drug is used according to its package leaflet in clinical practice, evaluate the treatment's efficacy, and determine its cost.</p></div><div><h3>Methods</h3><p>Ambispective, observational single-centre study of medication use set up as a prescription evaluation for the indication of rituximab in a tertiary hospital between March 2003 and December 31, 2007.</p></div><div><h3>Results</h3><p>Eighty-two of the 221 patients who were treated (37.1%) received the drug for a condition that does not appear in the package leaflet. Fifty-one point one percent and 27.5% of response and progression were registered for approved diagnoses and 34.9% and 47% for nonapproved diagnoses; the death rate was 25.3% and 41.5% respectively. The mean cost per treatment episode was the highest for idiopathic thrombocytopaenic purpura (#euro11 683), whilst the highest treatment cost per patient was associated with follicular lymphoma (€15 940).</p></div><div><h3>Discussion</h3><p>We found that the main cause of the high rate of non-compliance with the package leaflet is patient lack of response to standard treatments, together with clinical practice guides that support the use of rituximab for conditions other than those for which it is indicated. Nevertheless, most of the clinical trials evaluating the efficacy of rituximab for these unauthorised diagnostic profiles have poor methodology, are in phase II, are open studies, have low patient numbers, or in some cases, are not comparative.</p></div>","PeriodicalId":100521,"journal":{"name":"Farmacia Hospitalaria (English Edition)","volume":"33 6","pages":"Pages 305-311"},"PeriodicalIF":0.0,"publicationDate":"2009-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S2173-5085(09)70094-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56620737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Biologic therapies for systemic autoimmune diseases. Are expectations met? 系统性自身免疫性疾病的生物疗法。是否达到了预期?

Farmacia Hospitalaria (English Edition) Pub Date : 2009-01-01 DOI: 10.1016/S2173-5085(09)70070-X

L. Pallarés Ferreres , M. Ramos-Casals

引用次数: 0

Negative results related to drugs required in hospitalisation 与住院期间所需药物相关的阴性结果

Farmacia Hospitalaria (English Edition) Pub Date : 2009-01-01 DOI: 10.1016/S2173-5085(09)70064-4

A. Santamaría-Pablos , C. Redondo-Figuero , M.I. Baena , M.J. Faus , R. Tejido , O. Acha , F.J. Novo

{"title":"Negative results related to drugs required in hospitalisation","authors":"A. Santamaría-Pablos , C. Redondo-Figuero , M.I. Baena , M.J. Faus , R. Tejido , O. Acha , F.J. Novo","doi":"10.1016/S2173-5085(09)70064-4","DOIUrl":"10.1016/S2173-5085(09)70064-4","url":null,"abstract":"<div><h3>Objective</h3><p>To assess the prevalence of negative clinical outcomes associated with medication as a cause of hospital admission and to determine their characteristics (types, categories, avoidability, severity, and the drug groups involved). To determine possible risk factors related to the appearance of this problem.</p></div><div><h3>Method</h3><p>An observational study carried out over a 3 month period in a department of the university hospital, 163 patients were selected at random. The information obtained from the patient interview, the revision of clinical records and clinical sessions were used to then identify negative clinical outcomes using the Dader method.</p></div><div><h3>Results</h3><p>In 27 cases (16.6%; 95% confidence interval [CI], 1.6–23.0), negative clinical outcomes associated with medication were considered to be the main cause of hospital admission. The most frequent negative clinical outcomes associated with medication were untreated health problems, non-quantitative ineffectiveness, and quantitative safety problems respectively. The overall prevalence of preventable admissions due to negative clinical outcomes associated with medication was 88.9%; (95% CI, 71.9–96.1). With regards to severity, 74.1% (95% CI, 55.3–86.1) of the total admissions were moderate. The most common drugs implicated in hospital admissions were: antibacterial for systemic use, cardiovascular, and non steroidal anti-inflammatory agents. Apart from age, no other factors were found for hospital admissions due to negative results associated with medication.</p></div><div><h3>Conclusions</h3><p>Negative clinical outcomes associated with medication as cause of hospital admission are a prevalent problem and most of them are avoidable with pharmacotherapeutic follow-up.</p></div>","PeriodicalId":100521,"journal":{"name":"Farmacia Hospitalaria (English Edition)","volume":"33 1","pages":"Pages 12-25"},"PeriodicalIF":0.0,"publicationDate":"2009-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S2173-5085(09)70064-4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81955980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Therapeutic use and profile of toxicity of the FOLFOX4 regimen FOLFOX4方案的治疗用途和毒性概况

Farmacia Hospitalaria (English Edition) Pub Date : 2009-01-01 DOI: 10.1016/S2173-5085(09)70074-7

B. Fernández-Lobato , M.S. Díaz-Carrasco , A. Pareja , M. Marín , N. Vila , A. de la Rubia

{"title":"Therapeutic use and profile of toxicity of the FOLFOX4 regimen","authors":"B. Fernández-Lobato , M.S. Díaz-Carrasco , A. Pareja , M. Marín , N. Vila , A. de la Rubia","doi":"10.1016/S2173-5085(09)70074-7","DOIUrl":"10.1016/S2173-5085(09)70074-7","url":null,"abstract":"<div><h3>Introduction</h3><p>Since the publication of the MOSAIC test results in 2004, the FOLFOX4 regimen has been established as an adjuvant treatment which is recommended in stage III colorectal cancer. The aim of this study is to assess the use of this regimen in our field and to describe its toxicity.</p></div><div><h3>Methods</h3><p>Descriptive study of treatments with FOLFOX4 prescribed between April 2005 and March 2007. The data was obtained from the Farhos Oncología® programme and clinical records. The following data was collected: age, gender, diagnosis, stage of the illness (TNM classification), and adverse reactions, expressing severity according to Common Toxicity Criteria 2.0.</p></div><div><h3>Results</h3><p>The FOLFOX4 regimen was prescribed for 39 patients (24 men and 15 women) with an average age of 59. The diagnoses were: 28 colon cancer (4 stage II, 17 stage III, and 7 stage IV), 10 rectal cancer (1 stage II, 4 stage III, and 5 stage IV), and 1 stage IV gastric cancer. The most frequent adverse reactions were peripheral neuropathy (82%), neutropaenia (56.4%), and diarrhoea (53.9%). When the study was completed, 9 patients continued active treatment with the regimen (average, 6.8 cycles). Of the 30 remaining patients only 16 people completed the 12 planned cycles. Forteen patients stopped their treatment (average, 8.1 cycles) due to toxicity in 10 cases, clinical progression in 3 cases, and 1 patient died. Of the total 368 cycles administered, 68 suffered administration delays and 22 had the dosage reduced.</p></div><div><h3>Conclusion</h3><p>The use of the FOLFOX4 regimen has been adjusted to uses with some solid scientific evidence, but its toxicity has limited its use and has made administering the planned dosage levels difficult.</p></div>","PeriodicalId":100521,"journal":{"name":"Farmacia Hospitalaria (English Edition)","volume":"33 2","pages":"Pages 89-95"},"PeriodicalIF":0.0,"publicationDate":"2009-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S2173-5085(09)70074-7","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77806180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Work of a multidisciplinary team in the control of the prescription of ertapenem 多学科团队在厄他培南处方控制中的工作

Farmacia Hospitalaria (English Edition) Pub Date : 2009-01-01 DOI: 10.1016/S2173-5085(09)70069-3

M.V. Gil-Navarro , R. Muñoz-Corte , M. Herrero Romero , M.D. Santos Rubio , E. Cordero Matía , J. Bautista Paloma

{"title":"Work of a multidisciplinary team in the control of the prescription of ertapenem","authors":"M.V. Gil-Navarro , R. Muñoz-Corte , M. Herrero Romero , M.D. Santos Rubio , E. Cordero Matía , J. Bautista Paloma","doi":"10.1016/S2173-5085(09)70069-3","DOIUrl":"10.1016/S2173-5085(09)70069-3","url":null,"abstract":"<div><h3>Objective</h3><p>To determine the effectiveness of the intervention of a multidiscipline antimicrobial control group in the correct prescription of Ertapenem.</p></div><div><h3>Method</h3><p>A 4-month long, prospective study into prescriptions for ertapenem was carried out in a third-level hospital. Assessment into the degree of suitability of each prescription according to the infections commission usage criteria. In the situation where prescriptions were not suitable, recommendations were given and acceptance of this was recorded. The effectiveness of the antimicrobial treatment used was assessed and treatment was considered effective when there was remission of the signs and symptoms of the infection when the treatment was completed. The treatment was considered to have failed when the signs and symptoms of infection persisted or progressed, requiring the addition of another antimicrobial agent, changing antibiotics or the prolongation of the treatment for longer than 2 weeks. Lastly, the differences in the average length of stay and the duration of the antibiotic treatment between groups were analysed.</p></div><div><h3>Results</h3><p>Forty-eight prescriptions were assessed. The usage criterion was adequate in 48% of cases, with 78% effectiveness in this group. In the cases where the prescription was not adequate, but a change in prescription was accepted, the effectiveness was 92%, with 55.5% of those cases not accepting recommendation for change. The average stay was higher in this last group (P=.07). The duration of the antibiotic treatment in the patients who accepted the change in prescription was significantly less than in those who did not accept it (2 vs 7.4 days, P<.0001).</p></div><div><h3>Conclusions</h3><p>The control of ertapenem prescriptions by a multidisciplinary group was effective.</p></div>","PeriodicalId":100521,"journal":{"name":"Farmacia Hospitalaria (English Edition)","volume":"33 1","pages":"Pages 48-52"},"PeriodicalIF":0.0,"publicationDate":"2009-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S2173-5085(09)70069-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84498706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

The influence of alternative medicine in highly active antiretroviral treatment 替代药物对高活性抗逆转录病毒治疗的影响

Farmacia Hospitalaria (English Edition) Pub Date : 2009-01-01 DOI: 10.1016/S2173-5085(09)70066-8

M. Vázquez Hernández , M.F. Hurtado Gómez , J.R. Blanco

{"title":"The influence of alternative medicine in highly active antiretroviral treatment","authors":"M. Vázquez Hernández , M.F. Hurtado Gómez , J.R. Blanco","doi":"10.1016/S2173-5085(09)70066-8","DOIUrl":"10.1016/S2173-5085(09)70066-8","url":null,"abstract":"<div><h3>Objective</h3><p>Over the last few years, there has been a notable increase in the use of alternative medicine by the general population. The aim of this study is 2-fold. Firstly we will analyse the incidence of the use of medicinal plants in patients with HIV undergoing Highly Active Anti-Retroviral Therapy (HAART). Secondly, with the help of existing bibliographic information, we want to study the existence of possible interactions.</p></div><div><h3>Material and method</h3><p>We carried out a prospective study with a targeted interview (October to December 2007) on consenting patients with HIV undergoing HAART treatment.</p></div><div><h3>Results</h3><p>Of the 193 patients that agreed to take part in the survey, 16.6% confirmed they used alternative medicinal therapies. In 46% of the cases there was a potential interaction with the effectiveness of HAART. Forty-six percent of the potential interactions were in the case of the patients who used grapefruit as an alternative medicine, 21% in the case of patients using thistle and Echinacea respectively, 4% for those using omega-3, Chinese herbs, and ginseng.</p></div><div><h3>Conclusion</h3><p>There is a significant use of natural products by these groups of patients, of which a significant percentage interact with HAART. A better understanding of the possible interactions with HAART and improved information offered to patients with HIV is needed.</p></div>","PeriodicalId":100521,"journal":{"name":"Farmacia Hospitalaria (English Edition)","volume":"33 1","pages":"Pages 31-36"},"PeriodicalIF":0.0,"publicationDate":"2009-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S2173-5085(09)70066-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80078963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 9

Comparison of two formulae for the calculation of glomerular filtration in the dosage of zoledronic acid 两种计算唑来膦酸剂量肾小球滤过率公式的比较

Farmacia Hospitalaria (English Edition) Pub Date : 2009-01-01 DOI: 10.1016/S2173-5085(09)70065-6

E. Ramírez Herráiz , N. Garrido Peño , R. Díez Fernández , A.M. Iglesias Bolaños , M. Arteta Jiménez

{"title":"Comparison of two formulae for the calculation of glomerular filtration in the dosage of zoledronic acid","authors":"E. Ramírez Herráiz , N. Garrido Peño , R. Díez Fernández , A.M. Iglesias Bolaños , M. Arteta Jiménez","doi":"10.1016/S2173-5085(09)70065-6","DOIUrl":"10.1016/S2173-5085(09)70065-6","url":null,"abstract":"<div><h3>Objective</h3><p>To validate the use of a formula that does not require the patient's weight (Levey formula) for calculating creatinine clearance in the adjustment of the dosage of zoledronic acid.</p></div><div><h3>Method</h3><p>Prospective observational study in which zoledronic acid prescriptions in the Oncology and Haematology departments were recorded over the course of 8 months. The adjustment of the dose of zoledronic acid was carried out in accordance with creatinine clearance obtained using 2 different equations; the Cockcroft-Gault equation which is based on medical records, and the Levey formula which does not require the patient's weight for the calculation. The results of zoledronic acid dosage from both equations were compared using the SPSS statistics programme, via the comparison of the 2 measurements using the t Student-Fisher (t test).</p></div><div><h3>Results</h3><p>The t test provided a t test value of t=−3.366, with 112 degrees of freedom and a degree of bilateral importance of P=.001. The difference between both measurements was d=−0.051[0.162]) and the confidence interval was 95%, −0.082 to −0.021. From the data obtained in the t test, the degree of bilateral importance (P=.001 <.05) indicated that the results of the test were statistically significant.</p></div><div><h3>Conclusions</h3><p>The difference between the dosages obtained when comparing both methods of glomerular filtration is statistically significant, although not clinically relevant, therefore the MDRD-4 formula (Levey) could be used if the patient's weight is not available.</p></div>","PeriodicalId":100521,"journal":{"name":"Farmacia Hospitalaria (English Edition)","volume":"33 1","pages":"Pages 26-30"},"PeriodicalIF":0.0,"publicationDate":"2009-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S2173-5085(09)70065-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56619130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1